

Annual Review of PPI Antiulcer Category - Fiscal Year 2011
 Oklahoma HealthCare Authority
 April 2012

Current Prior Authorization Criteria

Criteria for Approval of a Tier-2 medication:

1. A 14-day trial of all available Tier 1 medications titrated up to the recommended dose that has resulted in inadequate relief of symptoms or intolerable adverse effects.
2. Contraindication to all available Tier 1 medications.
3. An indication not covered by lower tiered medications.

Criteria for Approval of a Tier-3 medication:

1. A 14-day trial all available Tier 2 medications that has resulted in inadequate relief of symptoms or intolerable adverse effects.
2. Contraindication to all available Tier 2 medications.
3. An indication not covered by lower tiered medications.

Criteria for Approval of Age Appropriate PPIs for Pediatric Members under the age of 19:

1. A recent 14-day trial of an H₂ receptor antagonist that has resulted in inadequate relief of symptoms or intolerable adverse effects.
2. Recurrent or severe disease such as:
 - a. GI bleed
 - b. Zollinger-Ellison or similar disease

Tier 1	Tier 2	Tier 3
Omeprazole (Prilosec)	dexlansoprazole (Dexilant®)	omeprazole (Prilosec Susp)*
Pantoprazole (Protonix® Tabs)	lansoprazole (Prevacid® & ODT)*	esomeprazole (Nexium® Caps and I.V.)*
		pantoprazole (Protonix® Susp & I.V.)*
		rabeprazole sodium (Aciphex® Tabs)

Special Prior Authorization Criteria for Miscellaneous Products

- ranitidine (Zantac® Effervescent Tabs) – must have reason why member cannot take other dosage forms.
- Pepcid® Suspension (famotidine) – reserved for members less than 1 month old.
- omeprazole/sodium bicarbonate – only generic products covered, and requires special reason for use.

Quantity Limits Apply:


- Omeprazole 10 mg: #60 for 30 days
- Omeprazole 20 mg: #120 for 30 days
- All other PPI's: #30 for 30 days

Utilization of PPI Anti-ulcer Medications


Comparison of Fiscal Years

Fiscal Year	Members	Claims	Cost	Cost /Claim	Cost/Day	Units	Days
2010	26,322	107,183	\$6,959,406.50	\$64.93	\$2.03	4,170,783	3,430,330
2011	28,713	117,207	\$4,329,274.42	\$36.94	\$1.15	4,672,692	3,779,906
% Change	9.10	9.40	-37.80	-43.10	-43.30	12.00	10.20
Change	2391	10,024	\$2,630,132.08	\$27.99	\$0.88	501,909	349,576

Demographics of Members: FY 2011




Prescriber Specialties by Number of Claims: FY 2011



Prior Authorization of PPI Anti-ulcer Medications

There were a total of 6,419 petitions submitted for this PBPA category during fiscal year 2011. The following chart shows the status of the submitted petitions.



Market News and Update

- Aciphex® (rabeprazole) – anticipated to expire in 2013
- Nexium® (esomeprazole) – anticipated to expire in 2014
- Dexilant® (dexlansoprazole) – anticipated to expire in 2020
- Pantoprazole (Protonix®) was moved to tier-1 effective 2/1/2011 due to change in cost making it comparable to the other Tier 1 medication, omeprazole.
- March 2, 2011: FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs)
- April 15, 2011: FDA sent letters to Healthcare Professionals regarding: communication on lansoprazole delayed-release orally disintegrating tablets manufactured by Teva. Pharmaceuticals are potentially clogging oral syringes and feeding tubes with the precaution to use another generic manufacturer in these cases.
- March 23, 2011 update: FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors

Conclusion and Recommendations

The College of Pharmacy recommends no changes to the Proton Pump Inhibitor Product based prior authorization category at this time.

Utilization Details of PPI Anti-ulcer Medications: Fiscal Year 2011

CHEMICAL NAME	BRAND NAME	CLAIMS	MEMBERS	COST	UNITS/DAY	CLAIM/MEMBER	% COST
Dexlansoprazole	DEXILANT CAP 30MG DR	335	93	\$40,919.79	1	3.6	0.95%
Dexlansoprazole	KAPIDEX CAP 30MG DR	11	7	\$1,297.15	1	1.57	0.03%
Dexlansoprazole	DEXILANT CAP 60MG DR	2,392	531	\$292,513.72	1	4.5	6.76%
Dexlansoprazole	KAPIDEX CAP 60MG DR	26	15	\$2,709.25	1	1.73	0.06%
Subtotals		2,764		\$337,439.91	1	2.85	7.80%
Esomeprazole	NEXIUM GR 10MG DR	16	2	\$4,468.92	1.56	8	0.10%
Esomeprazole	NEXIUM GR 20MG DR	21	3	\$5,728.17	1.52	7	0.13%
Esomeprazole	NEXIUM GR 40MG DR	25	4	\$3,604.03	1	6.25	0.08%
Esomeprazole	NEXIUM CAP 20MG	292	49	\$51,334.93	1	5.96	1.19%
Esomeprazole	NEXIUM CAP 40MG	5,685	754	\$1,014,915.42	1.03	7.54	23.44%
Subtotals		6,039		\$1,080,051.47	1.03	6.95	24.94%
Lansoprazole	LANSOPRAZOLE CAP 15MG	1,516	282	\$94,825.53	1.02	5.38	2.19%
Lansoprazole	LANSOPRAZOLE CAP 30MG	10,739	1,562	\$676,209.77	1.1	6.88	15.62%
Lansoprazole	PREVACID CAP 30MG DR	2	1	\$353.54	1	2	0.01%
Lansoprazole	PREVACID TAB 15MG STB	532	154	\$88,575.60	0.98	3.45	2.05%
Lansoprazole	LANSOPRAZOLE 15MG ODT	362	158	\$49,708.03	0.99	2.29	1.15%
Lansoprazole	PREVACID TAB 30MG STB	261	61	\$45,003.75	1.06	4.28	1.04%
Lansoprazole	LANSOPRAZOLE 30MG ODT	149	55	\$20,011.98	1.07	2.71	0.46%
Subtotals		13,561		\$974,688.20	1.08	3.85	22.52%
Omeprazole	OMEPRAZOLE CAP 10MG	1,897	747	\$32,367.81	1.09	2.54	0.75%
Omeprazole	OMEPRAZOLE CAP 20MG	68,806	20,464	\$1,087,518.46	1.34	3.36	25.12%
Omeprazole	OMEPRAZOLE CAP 40MG	14,507	5,070	\$221,867.99	1.1	2.86	5.12%
Omeprazole	PRILOSEC POW 2.5MG	47	22	\$9,717.23	0.83	2.14	0.22%
Omeprazole	PRILOSEC POW 10MG	78	36	\$14,127.51	1.14	2.17	0.33%
Subtotals		85,335		\$1,365,599.00	1.30	2.614	31.54%
Pantoprazole	PANTOPRAZOLE TAB 20MG	353	139	\$14,115.75	1.02	2.54	0.33%
Pantoprazole	PANTOPRAZOLE TAB 40MG	7,909	2,066	\$316,202.45	1.03	3.83	7.30%
Pantoprazole	PROTONIX TAB 40MG	23	8	\$2,519.26	1	2.88	0.06%
Pantoprazole	PROTONIX INJ 40MG	87	3	\$1,452.03	1	29	0.03%
Pantoprazole	PROTONIX PAK	51	9	\$7,333.69	1.03	5.67	0.17%
Subtotals		8,423		\$341,623.18	1.03	8.784	7.89%
Rabeprazole	ACIPHEX TAB 20MG	1,085	134	\$229,872.66	1.01	8.1	5.31%
Total		117,207	28,713*	\$4,329,274.42	1.24	4.08	100.00%

*Total unduplicated number of members